AbstractBackgroundThe past three decades have seen rapid improvements in the diagnosis and treatment of most cancers and the most important contributor has been research. Progress in rare cancers has been slower, not least because of the challenges of undertaking research.SettingsThe International Rare Cancers Initiative (IRCI) is a partnership which aims to stimulate and facilitate the development of international clinical trials for patients with rare cancers. It is focused on interventional – usually randomised – clinical trials with the clear goal of improving outcomes for patients. The key challenges are organisational and methodological. A multi-disciplinary workshop to review the methods used in ICRI portfolio trials was held in Amst...
To date, the Rare Cancer Network (RCN) has initiated more than 90 studies and 54 peer-reviewed publi...
To date, the Rare Cancer Network (RCN) has initiated more than 90 studies and 54 peer-reviewed publi...
Purpose: Epidemiologic information on rare cancers is scarce. The project Surveillance of Rare Cance...
BACKGROUND: The past three decades have seen rapid improvements in the diagnosis and treatment of mo...
AbstractBackgroundThe past three decades have seen rapid improvements in the diagnosis and treatment...
BACKGROUND: The past three decades have seen rapid improvements in the diagnosis and treatment of mo...
Introduction: Rare cancers together account for about 22% of new cancer diagnoses each year, which i...
Background The past three decades have seen rapid improvements in the diagnosis and treatment of mo...
The past three decades have seen rapid improvements in the diagnosis and treatment of most cancers a...
textabstractWhile they account for one-fifth of new cancer cases, rare cancers are difficult to stud...
Background: Orphan drug development faces numerous challenges, including low disease prevalence, pat...
In 2017, the International Rare Diseases Research Consortium (IRDiRC) set out ambitious goals, one o...
While they account for one-fifth of new cancer cases, rare cancers are difficult to study. A higher ...
More than 50 % of all gynecologic cancers can be classified as rare tumors (defined as an incidence ...
Rare diseases are diseases with prevalence of lower than one in 2,000 individuals. Jointly, rare dis...
To date, the Rare Cancer Network (RCN) has initiated more than 90 studies and 54 peer-reviewed publi...
To date, the Rare Cancer Network (RCN) has initiated more than 90 studies and 54 peer-reviewed publi...
Purpose: Epidemiologic information on rare cancers is scarce. The project Surveillance of Rare Cance...
BACKGROUND: The past three decades have seen rapid improvements in the diagnosis and treatment of mo...
AbstractBackgroundThe past three decades have seen rapid improvements in the diagnosis and treatment...
BACKGROUND: The past three decades have seen rapid improvements in the diagnosis and treatment of mo...
Introduction: Rare cancers together account for about 22% of new cancer diagnoses each year, which i...
Background The past three decades have seen rapid improvements in the diagnosis and treatment of mo...
The past three decades have seen rapid improvements in the diagnosis and treatment of most cancers a...
textabstractWhile they account for one-fifth of new cancer cases, rare cancers are difficult to stud...
Background: Orphan drug development faces numerous challenges, including low disease prevalence, pat...
In 2017, the International Rare Diseases Research Consortium (IRDiRC) set out ambitious goals, one o...
While they account for one-fifth of new cancer cases, rare cancers are difficult to study. A higher ...
More than 50 % of all gynecologic cancers can be classified as rare tumors (defined as an incidence ...
Rare diseases are diseases with prevalence of lower than one in 2,000 individuals. Jointly, rare dis...
To date, the Rare Cancer Network (RCN) has initiated more than 90 studies and 54 peer-reviewed publi...
To date, the Rare Cancer Network (RCN) has initiated more than 90 studies and 54 peer-reviewed publi...
Purpose: Epidemiologic information on rare cancers is scarce. The project Surveillance of Rare Cance...